Chemical Namegadoterate meglumine
Dosage FormInjection (intravenous; 0.2 mL/kg (0.1 mmol/kg))
Drug ClassMiscellaneous
CompanyGuerbet LLC
Approval Year2013


  • Indicated for use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.
Last updated on 4/27/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Dotarem (gadoterate meglumine) Prescribing Information2013Guerbet LLC, Princeton, New Jersey